PureTech Health (LSE:PRTC) 12-1 Month Momentum % : -4.92% (As of May. 28, 2024)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-28), PureTech Health's 12-1 Month Momentum % is -4.92%.

The industry rank for PureTech Health's 12-1 Month Momentum % or its related term are showing as below:

LSE:PRTC's 12-1 Month Momentum % is ranked better than
66.62% of 1477 companies
in the Biotechnology industry
Industry Median: -25.37 vs LSE:PRTC: -4.92

Competitive Comparison of PureTech Health's 12-1 Month Momentum %

For the Biotechnology subindustry, PureTech Health's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where PureTech Health's 12-1 Month Momentum % falls into.

PureTech Health (LSE:PRTC) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PureTech Health (LSE:PRTC) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

PureTech Health 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of PureTech Health's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health (LSE:PRTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (LSE:PRTC) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

PRTC:USA PTCHF:USA PRTCl:UK PRTCL:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.